5 mg Serlopitant Tablets

DRUG4 trials

Sponsors

Vyne Therapeutics Inc.

Conditions

Atopic DermatitisPrurigo NodularisPruritusPsoriasisRefractory Chronic Cough

Phase 2

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough

CompletedNCT03282591

Vyne Therapeutics Inc.Refractory Chronic Cough

Start: 2017-10-03End: 2018-09-06Updated: 2021-05-20

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis

CompletedNCT03343639

Vyne Therapeutics Inc.Pruritus, Psoriasis

Start: 2017-11-01End: 2018-11-12Updated: 2021-05-20

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin

CompletedNCT03841331

Vyne Therapeutics Inc.Pruritus

Start: 2019-01-22End: 2020-01-21Updated: 2021-05-20

Phase 3

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

TerminatedNCT03540160

Vyne Therapeutics Inc.Atopic Dermatitis, Prurigo Nodularis, Pruritus +1

Start: 2018-03-15End: 2020-06-17Updated: 2021-05-20

Related Papers

Evaluation of apremilast in chronic pruritus of unknown origin: A proof‐of‐concept, phase 2a, open‐label, single‐arm clinical trial

Health Science Reports2020-04-2311 citations

Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial

BMJ Open2020-02-0112 citations

Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial.

2020-01-3032 citations

Sensitization Mechanisms of Chronic Itch

International Journal of Dermatology and Venereology2019-09-1810 citations